Şeyda Gündüz

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

Ajjai Alva, Tibor Csőszi, Mustafa Özgüroğlu et al. · Annals of Oncology · 2020 · 67 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Silk Embolic Material for Catheter‐Directed Endovascular Drug Delivery

Jingjie Hu, Hassan Albadawi, Zefu Zhang et al. · Advanced Materials · 2021 · 59 citations · Full text

Pharmacy, Bioengineering, Pharmaceutics +17

Robotic Devices for Minimally Invasive Endovascular Interventions: A New Dawn for Interventional Radiology

Şeyda Gündüz, Hassan Albadawi, Rahmi Öklü · Advanced Intelligent Systems · 2020 · 40 citations · Full text

Engineering, Autonomous Systems, Radiology +17

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

Thomas Powles, Yen‐Hwa Chang, Yoshiaki Yamamoto et al. · Nature Medicine · 2024 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17